Article metrics

Download PDFPDF
Extended report
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

 

Online download statistics by month:

Online download statistics by month: April 2014 to August 2020

AbstractFullPdf
Apr 201458451154
May 20143098281
Jun 20141093135
Jul 20142612432
Aug 20141373426
Sep 20141462836
Oct 2014983231
Nov 2014752024
Dec 2014651013
Jan 2015652118
Feb 2015701421
Mar 2015712216
Apr 2015531916
May 2015572321
Jun 2015521410
Jul 2015591320
Aug 2015168598142
Sep 20158994381
Oct 20152652036
Nov 20152152833
Dec 20151822629
Jan 20161802837
Feb 20161192320
Mar 2016911519
Apr 20161153233
May 20161061821
Jun 2016943831
Jul 2016901115
Aug 20161112522
Sep 20161613039
Oct 20161432431
Nov 2016972927
Dec 2016921354
Jan 20171011113
Feb 201711299
Mar 20171191913
Apr 20171042420
May 2017841411
Jun 201712299
Jul 2017186910
Aug 2017266811
Sep 20171861516
Oct 20172151310
Nov 20172261213
Dec 20171751111
Jan 20181761413
Feb 2018147611
Mar 201816293
Apr 20181862212
May 201829595
Jun 201812887
Jul 201811977
Aug 2018116162
Sep 201810572
Oct 201811368
Nov 20182482311
Dec 2018120165
Jan 2019711012
Feb 201910142
Mar 201912377
Apr 20198288
May 20197687
Jun 20193455
Jul 20196485
Aug 20197154
Sep 20194178
Oct 20196334
Nov 20197354
Dec 201910299
Jan 202062116
Feb 2020115157
Mar 202013967
Apr 202011773
May 202088117
Jun 20207976
Jul 202010596
Aug 20205778
Total1233013881581